In patients with AML treated by allogeneic HSCT, IL‐22 secreted by ILC3s might forestall graft versus host disease (GVHD), and thus IL‐22 could be a feasible treatment option (Munneke et al., 2014). Here, IL22 is linked to graft versus host disease.